European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season
Go back to European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season| Merck & Co. (NYSE: MRK) | Delayed: 115.47 +1.60 (1.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $113.87 | 52 Week High | $65.46 | |||
| Open | $113.97 | 52 Week Low | $47.97 | |||
| Day High | $115.56 | P/E | 78.55 | |||
| Day Low | $113.00 | EPS | $1.47 | |||
| Volume | 3,535,328 | |||||
